Robert Driscoll
Stock Analyst at Wedbush
(0)
# 4775
Out of 5,298 analysts
201
Total ratings
19.42%
Success rate
-26.50%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
ZNTL Zentalis Pharma | Reiterates: Neutral | 4 4 | 1.27 | 214.96% | 10 | Mar 28, 2025 | |
GLUE Monte Rosa Therapeut... | Maintains: Outperform | 15 17 | 3.81 | 346.19% | 4 | Mar 21, 2025 | |
HOWL Werewolf Therapeutic... | Reiterates: Outperform | 8 8 | 0.75 | 966.67% | 2 | Mar 12, 2025 | |
ARVN Arvinas | Downgrades: Neutral | 57 12 | 6.63 | 81% | 9 | Mar 12, 2025 | |
DAWN Day One Biopharmaceu... | Reiterates: Outperform | 32 32 | 7.42 | 331.27% | 6 | Feb 26, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 34 36 | 6.07 | 493.08% | 8 | Feb 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 52 | 15.32 | 239.43% | 9 | Dec 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 70 67 | 32.18 | 108.2% | 4 | Dec 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 28 28 | 8.09 | 246.11% | 8 | Oct 25, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 16 16 | 1.45 | 1003.45% | 10 | Oct 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 30 | 7.29 | 311.52% | 7 | Oct 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 25 22 | 1.14 | 1829.82% | 10 | Oct 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 85 51 | 4.93 | 934.48% | 1 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 5 5 | 0.68 | 635.29% | 8 | Sep 20, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 36 36 | 7.52 | 378.72% | 4 | Sep 18, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 11 11 | 1.72 | 539.53% | 3 | Aug 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 13 13 | 3.75 | 246.67% | 7 | Aug 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 11 13 | 1.28 | 915.62% | 4 | Aug 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 74 74 | 25.2 | 193.65% | 7 | Aug 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 12 12 | n/a | n/a | 4 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 1.61 | 396.89% | 3 | Aug 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 7 7 | 1.4 | 400% | 8 | Jun 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Neutral | 65 | n/a | n/a | 8 | May 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 3 8 | 0.48 | 1566.67% | 9 | May 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 8 8 | 0.24 | 3233.33% | 7 | May 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 52 | 7.5 | 593.33% | 5 | Nov 8, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 4 | Aug 14, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jun 20, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 3 | n/a | n/a | 3 | May 12, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 36 | n/a | n/a | 2 | Nov 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 50 70 | n/a | n/a | 4 | May 16, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 9 2 | n/a | n/a | 2 | Mar 8, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 136 17 | n/a | n/a | 3 | Mar 19, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 5 9 | n/a | n/a | 6 | Jun 22, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 2 4 | 3.35 | 19.4% | 4 | May 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 1500 250 | n/a | n/a | 1 | Mar 19, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 17 3 | n/a | n/a | 3 | Nov 12, 2018 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 30 34 | n/a | n/a | 1 | Apr 4, 2017 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 120 160 | n/a | n/a | 1 | Feb 22, 2017 |